Radiation Free Chemotherapy for Early Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2026-07-02
Target enrollment:
Participant gender:
Summary
The results of the present study will provide information on short-term safety and efficacy
of a iPET and MTV-adapted therapeutic strategy, aimed to assess the feasibility and safety on
immediate disease control of a standard ABVD chemotherapy without any further treatment in
patients with a very low risk or treatment failure. A second very important endpoint will be
the efficacy of INRT "on demand" followed by Nivolumab maintenance for one year to rescue
patients failing first-line treatment and relapsing with the pattern of "limited relapse" in
terms of 3-Y failure from 2 relapse (FF2R). Patients entering into the study will be also
asked to participate to a long-term follow up study (beyond ten years) to assess the
prevalence of late-onset cardiovascular effects and secondary tumors in the cohort of
patients enrolled in the experimental and control arm of the study. An exploratory endpoint
has been also added such as the role of Minimal Residual Disease (MRD) detection by cell-free
DNA assay on peripheral blood samples obtained during treatment in predicting long-term
disease control.